Flindr Therapeutics B.V. secures €20 million in Series A financing led by V-Bio Ventures to advance its innovative precision oncology pipeline targeting cancer through first-in-class small molecule inhibitors.

Information on the Target

Flindr Therapeutics B.V. ("Flindr" or "the Company") is an innovative precision oncology therapeutics company specializing in the discovery and development of targeted therapies aimed at eradicating tumors in specific patient populations. Established in 2020, Flindr has developed a strong foundation built on world-class scientific knowledge and extensive expertise in translational biology, cancer target identification, as well as immuno-oncology and small molecule oncology drug development. The Company's dedicated team boasts a proven track record in advancing covalent small molecule inhibitors from the discovery phase to market approval.

At the forefront of Flindr’s pipeline is a first-in-class small molecule inhibitor of RNF31, a protein involved in malignancies. This drug candidate has demonstrated promising efficacy in preclinical models targeting ovarian cancer and B-cell lymphoma. The Company’s commitment to leveraging cutting-edge research underpins its mission to revolutionize cancer treatment by advancing its lead program to Investigational New Drug (IND) status and developing additional avenues of therapeutic intervention.

Industry Overview in the Netherlands

The Netherlands boasts a robust life sciences and healthcare sector, which has experienced significant growth and innovation in recent years. With a wealth of research institutes and universities, like the Netherlands Cancer Institute and VIB, the country fosters a vibran